Results of ADOPT Trial Give Boost To Rosiglitazone: Cardiovascular events cause some concern.

A large, multinational study showing that rosiglitazone monotherapy was associated with a lower treatment failure rate at 5 years than either metformin or glyburide has fueled debate over whether thiazolidinediones should be considered for first-line therapy in type 2 diabetes.